Antibody and markers of T-cell activation illuminate the pathogenesis of HCV immune restoration disease in HIV/HCV co-infected patients commencing ART

  • Yunihastuti, E. [1], Lee, S. [2], Gani, R. A. [3], Saraswati, H. [4], Sundaru, H. [5], Lesmana, L. A. [6], Sukmana, N. [7], Price, P. [8],
  • Clinical Immunology
  • 139
  • Access here
  • Feb. 5, 2011
BIBLIOGRAPHY

Yunihastuti, E., Lee, S., Gani, R. A., Saraswati, H., Sundaru, H., Lesmana, L. A., Sukmana, N., & Price, P. (2011). Antibody and markers of T-cell activation illuminate the pathogenesis of HCV immune restoration disease in HIV/HCV co-infected patients commencing ART. Clinical Immunology (Orlando, Fla.), 139(1), 32–39. https://doi.org/10.1016/j.clim.2010.12.013
ABSTRAK

Some HIV/hepatitis C virus co-infected patients beginning ART experience Immune Restoration Disease (IRD) manifested as a rise in serum alanine transaminase. This was investigated in HIV/HCV co-infected individuals (n=50) commencing ART in Jakarta (Indonesia). Samples were collected at weeks 0, 4, 8, 12, 24 and at HCV IRD. Nine patients experienced HCV IRD (incidence=9.2 per 1000 person-weeks). These resolved without changing treatment. Markers of T-cell activation (sCD26, sCD30) and immune recruitment (CXCL10) increased in many HCV IRD cases, so T-cells may mediate HCV IRD. Total anti-HCV antibody (core, NS3, NS4) remained lower in HCV IRD cases, but levels of antibody to core were not lower in HCV IRD cases. Rises in HCV RNA on ART were independent of HCV IRD, but there was a negative correlation between baseline HCV RNA and total anti-HCV antibody. High levels of antibody may protect against HCV IRD, via lower HCV antigen loads.
ABSTRAK YANG BERHUBUNGAN